{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~$0.34 vs. cons $0.32",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Net Sales/Revenue (Q2 FY26)",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.03B vs. cons $4.00B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Skin Health & Beauty organic sales growth (Q2 FY26)",
      "prediction": "MISS",
      "answer": "pred ~4.0% vs. cons 5.0%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 formal guidance (suspended due to merger)",
      "prediction": "UNKNOWN",
      "answer": "guide ~withheld (implied $16.0B) vs. cons $16.0B (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "2026 Restructuring Initiative pre-tax charges",
      "prediction": "UNCHANGED",
      "answer": "guide ~$250M vs. cons $250M (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Deal timing (H2 2026 close, pending EU clearance)",
      "prediction": "UNCHANGED",
      "answer": "guide ~H2 2026 (0 new milestones) vs. cons H2 2026 (FY2026 close date)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -0.3,
  "day1_confidence": "LOW",
  "day5_residual_pct": -0.6,
  "day5_path": "FADE",
  "day5_rationale": "With no call and no restored guidance, any initial idiosyncratic pop from the EPS beat is likely to fade as (1) Skin Health & Beauty deceleration and continued Self Care softness raise implicit out-quarter estimate cuts even absent formal guidance, (2) the stock remains arbitrage-anchored to the fixed KMB exchange ratio (~$19.94 implied value) rather than standalone fundamentals, capping upside, and (3) the revived Tylenol autism litigation and pending EU merger clearance remain overhangs that dominate multi-day price action over fundamentals, pulling the initial reaction back toward the deal-implied spread within the week.",
  "day5_confidence": "LOW"
}